Skip to main content
. Author manuscript; available in PMC: 2022 Apr 5.
Published in final edited form as: Cancer Cell. 2021 Jul 21;39(8):1115–1134.e12. doi: 10.1016/j.ccell.2021.06.016

Figure 5. Epithelial-to-SCN cancer is a YAPon to YAPoff switch.

Figure 5.

(A) IHC on a murine lung model with mixed NSCLC (Syp–/Yap+) and NE (Syp+/Yap–) histology. Scale bar, 100 µm.

(B) IHC in murine PrAd (SKO: Pten–/–) or NEPC (DKO: Pten–/–;Rb1–/– or TKO:Pten–/–;Rb1–/–;p53–/–). Scale bar, 100 µm.

(C) PC1/3 gene levels in murine prostate cancer (cf. Figure 3C).

(D) PC1/3 gene enrichment in a ranked list (Table S5) distinguishing murine PrAd and NEPC confirms these prostate tumors are YAPon and YAPoff cancers, respectively.

(E) IHC on emerging NE tumors in 11-week murine TKO prostate. Scale bars, 100 µm (top), 20 µm (bottom).

(F) Multispectral IHC of mixed human NEPC (SYP+) and PrAd (SYP–). Only PrAd (dotted area) and blood vessels (arrows) stain for YAP or YAP/TAZ.

(G) PARCB gene code to reprogram human primary epithelia to SCN cancer (Park et al., 2018).

(H) PC1/3 gene levels in primary human epithelia or SCN cancer derived as in (G) (cf. Figure 3C).

(I) PC1/3 gene enrichment in a ranked list (Table S5) distinguishing the two states in (G) confirms the PARCB genes induce YAPon to YAPoff reprogramming.

See also Table S5.